| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Department of Neurology (Dr. Aisen), Georgetown University Medical Center, Washington, DC; and the Department of Psychiatry (Drs. Aisen, Schmeidler, and Pasinetti) and the Neuroinflammation Research Laboratories (Dr. Pasinetti), Department of Psychiatry, Mount Sinai Medical Center, New York, NY.
Address correspondence and reprint requests to Dr. Paul S. Aisen, Department of Neurology, Georgetown University Medical Center, 1 Bles Building, 3800 Reservoir Road, NW, Washington, DC 20007; e-mail: psa{at}georgetown.edu
Background: Nonsteroidal anti-inflammatory drugs (NSAID) may be useful in the treatment of AD. Clinical and laboratory experience with nimesulide, an NSAID with preferential cyclooxygenase-2 inhibition, suggests that it may be a good candidate for AD therapy.
Methods: This pilot study investigated the clinical feasibility of nimesulide treatment in AD. Forty persons with probable AD, most of whom were taking cholinesterase inhibitors, were enrolled in a randomized, controlled, parallel-group trial designed to assess tolerability and short-term cognitive/behavioral effects of nimesulide. In the initial 12-week double-blind phase, participants were treated with nimesulide 100 mg by mouth twice daily or matching placebo; during the second 12-week phase all participants received active drug. Participants who tolerated the drug well and perceived benefit were invited to continue open-label nimesulide treatment.
Results: Short-term therapy with nimesulide, compared with placebo, had no significant effect on total assessment scores of measures of cognition, clinical status, activities of daily living, affect, and behavior. Long-term therapy was well tolerated for periods exceeding 2 years.
Conclusion: These findings support the feasibility of nimesulide therapy in AD; assessment of efficacy will require a larger, long-term treatment study.
This article has been cited by other articles:
|
|
 |
|
  S. SALLOWAY and S. CORREIA Alzheimer disease: Time to improve its diagnosis and treatment Cleveland Clinic Journal of Medicine, January 1, 2009; 76(1): 49 - 58. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 ADAPT Research Group Cognitive Function Over Time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): Results of a Randomized, Controlled Trial of Naproxen and Celecoxib Arch Neurol, July 1, 2008; 65(7): 896 - 905. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. C. Vlad, D. R. Miller, N. W. Kowall, and D. T. Felson Protective effects of NSAIDs on the development of Alzheimer disease Neurology, May 6, 2008; 70(19): 1672 - 1677. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Hoshino, T. Nakaya, T. Homan, K.-i. Tanaka, Y. Sugimoto, W. Araki, M. Narita, S. Narumiya, T. Suzuki, and T. Mizushima Involvement of Prostaglandin E2 in Production of Amyloid-beta Peptides Both in Vitro and in Vivo J. Biol. Chem., November 9, 2007; 282(45): 32676 - 32688. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. M. Hayden, P. P. Zandi, A. S. Khachaturian, C. A. Szekely, M. Fotuhi, M. C. Norton, J. T. Tschanz, C. F. Pieper, C. Corcoran, C. G. Lyketsos, et al. Does NSAID use modify cognitive trajectories in the elderly?: The Cache County Study Neurology, July 17, 2007; 69(3): 275 - 282. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
ADAPT Research Group Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial Neurology, May 22, 2007; 68(21): 1800 - 1808. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J Ellul, N Archer, C M L Foy, M Poppe, H Boothby, H Nicholas, R G Brown, and S Lovestone The effects of commonly prescribed drugs in patients with Alzheimer's disease on the rate of deterioration J. Neurol. Neurosurg. Psychiatry, March 1, 2007; 78(3): 233 - 239. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. L. Sparks, M. N. Sabbagh, D. J. Connor, J. Lopez, L. J. Launer, P. Browne, D. Wasser, S. Johnson-Traver, J. Lochhead, and C. Ziolwolski Atorvastatin for the Treatment of Mild to Moderate Alzheimer Disease: Preliminary Results Arch Neurol, May 1, 2005; 62(5): 753 - 757. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. M. de Craen, J. Gussekloo, B. Vrijsen, and R. G. J. Westendorp Meta-Analysis of Nonsteroidal Antiinflammatory Drug Use and Risk of Dementia Am. J. Epidemiol., January 15, 2005; 161(2): 114 - 120. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. L. McGeer and E. McGeer Immunotherapy for Alzheimer's Disease Sci. Aging Knowl. Environ., July 7, 2004; 2004(27): pe29 - pe29. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. Etminan, S. Gill, and A. Samii Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies BMJ, July 17, 2003; 327(7407): 128. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Kaires and P. S. Aisen NSAID and the ancient defense Neurology, October 22, 2002; 59(8): 1293 - 1293. [Full Text] [PDF]
|
|
|
|
|
|
P. L. McGeer and E. G. McGeer Innate Immunity, Local Inflammation, and Degenerative Disease Sci. Aging Knowl. Environ., July 24, 2002; 2002(29): re3 - 3. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
